3-[2-[[4-[5-(2-aminopyrimidin-4-yl)benzimidazol-1-yl]-6-[2-(hydroxymethyl)phenyl]pyrimidin-2-yl]amino]ethyl]-N-phenylpiperidine-1-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-[2-[[4-[5-(2-aminopyrimidin-4-yl)benzimidazol-1-yl]-6-[2-(hydroxymethyl)phenyl]pyrimidin-2-yl]amino]ethyl]-N-phenylpiperidine-1-carboxamide
• 化学式: C₃₆H₃₆N₁₀O₂
• 分子量: 640.7
• InChiKey: VLKFRNGOOUQSEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  48
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• SRC KINASE INHIBITOR COMPOUNDS
  申请人：Merck & Co., Inc.

  公开号：EP1206260A1

  公开（公告）日：2002-05-22
• EP1206260A4
  申请人：——

  公开号：EP1206260A4

  公开（公告）日：2002-10-30
• [EN] SRC KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE LA SRC KINASE
  申请人：MERCK & CO INC

  公开号：WO2001000207A1

  公开（公告）日：2001-01-04

  Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogenesis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.